Pharmaceuticals

Short-Acting B2 Agonists Market 2025–2029: Tracking 4.1% CAGR Toward $5.18 Billion in Revenue

December 4, 2025 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the short-acting b2 agonists market from 2025–2034 with trusted insights from The Business Research Company

How Will The Short-Acting B2 Agonists Market Size Evolve Between Now And 2029?

The short-acting B2 agonist market size has experienced consistent expansion in recent years. It is projected to increase from $4.25 billion in 2024 to $4.4 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 3.4%. The market’s historical growth can be attributed to several factors, including an increase in the pediatric asthma population, a higher prevalence of environmental allergens, rising urbanization and pollution levels, an increased focus on the prevention of asthma exacerbations, and a growing number of research and development initiatives.

The short-acting B2 agonist market size is projected to experience consistent expansion over the upcoming years. This market is anticipated to reach a valuation of $5.18 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 4.1%. This projected growth during the forecast period is primarily driven by factors such as the increasing incidence of asthma and chronic obstructive pulmonary disease, heightened understanding of asthma care, a rise in government programs aimed at asthma and COPD therapy, escalating global healthcare spending, and an expanding elderly demographic. Key trends observed within this period encompass innovations in inhaler technologies, the expanding segment for individualized asthma therapies, user-friendly drug delivery methods, technological progress in nebulizers designed for home use, and refinements in drug formulations to enhance effectiveness.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24396&type=smp

Which Key Drivers Are Powering Growth In The Short-Acting B2 Agonists Market?

The rising incidence of chronic obstructive pulmonary disease (COPD) is anticipated to propel the expansion of the short-acting B2 agonists market in the coming years. COPD is a chronic lung condition marked by breathing difficulties and reduced airflow, primarily caused by prolonged exposure to harmful gases or cigarette smoke. The increase in COPD cases is attributed to heightened exposure to air pollution, as long-term inhalation of pollutants such as particulate matter and toxic gases can damage lung tissue and accelerate the disease’s development. Short-acting ß2-agonists (SABAs) are employed in COPD management to rapidly alleviate symptoms like shortness of breath by relaxing airway muscles. They serve as rescue medications during acute flare-ups but are not intended for long-term control. For example, according to data from July 2024 provided by the Australian Institute of Health and Welfare, an Australia-based government agency, chronic obstructive pulmonary disease (COPD) was responsible for 7,691 deaths in 2022, which translates to 29.6 per 100,000 population and represented 4.0% of all fatalities. Therefore, the increasing prevalence of chronic obstructive pulmonary disease is expected to boost the growth of the short-acting B2 agonists market.

How Is The Global Short-Acting B2 Agonists Market Structured By Key Segments?

The short-acting b2 agonists market covered in this report is segmented –

1) By Type: Albuterol, Levalbuterol, Metaproterenol, Other Types

2) By Indication: Asthama, Chronic Obstructive Pulmonary Disease (COPD), Exercise-Induced Bronchospasm

3) By Administration Route: Inhalation, Oral, Injection

4) By End User: Hospitals, Clinics, Home Healthcare Settings

Subsegments:

1) By Albuterol: Inhalers, Nebulizers, Tablets, Syrups

2) By Levalbuterol: Inhalers, Nebulizers, Oral Solutions

3) By Metaproterenol: Inhalers, Syrups

4) By Other Types: Terbutaline, Pirbuterol, Salbutamol

What Future-Focused Trends Are Anticipated In The Short-Acting B2 Agonists Market?

Leading firms within the short-acting B2 agonists market are concentrating on creating cutting-edge products, like pressurized metered-dose inhalers (pMDI), to effectively address acute symptoms. These pressurized metered-dose inhalers (pMDIs) are portable devices designed to dispense a precise quantity of medicine into the lungs as an aerosol via a propellant-powered spray, frequently employed for managing respiratory ailments such as asthma and COPD. An illustration of this is AstraZeneca, a UK-based pharmaceutical and biotechnology company, which revealed in January 2023, the US Food and Drug Administration (FDA) approval for Airsupra (albuterol/budesonide). Airsupra represents a novel pressurized metered-dose inhaler (pMDI) that integrates two active components within a fixed-dose composition. This product includes albuterol, categorized as a short-acting beta2-agonist (SABA), for swift bronchodilation, alongside budesonide, an inhaled corticosteroid (ICS), aimed at diminishing inflammation. This distinct blend is sanctioned in the US for the on-demand management and avoidance of bronchoconstriction among adult asthma sufferers. Furthermore, it contributes to lowering the likelihood of exacerbations, thereby offering a holistic strategy for asthma care.

Which Companies Hold A Competitive Edge In The Short-Acting B2 Agonists Market?

Major companies operating in the short-acting B2 agonists market are AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Apotex Inc., Perrigo Company plc, Aurobindo Pharma Ltd., Chiesi Farmaceutici S.p.A., Cipla Limited, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals Inc., Lupin Limited, Orion Corporation, Beximco Pharmaceuticals Ltd., Micro Labs Limited, Neuland Laboratories Limited, Vectura Group plc, Nephron Pharmaceuticals Corporation, AdvaCare Pharma USA LLC, Midas Care Pharmaceuticals Pvt Ltd.

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/short-acting-b2-agonists-global-market-report

Which Region Is Expected To Lead The Short-Acting B2 Agonists Market In The Next Few Years?

North America was the largest region in the short-acting B2 agonists market in 2024. The regions covered in the short-acting B2 agonists market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=24396&type=smp

Browse Through More Reports Similar to the Global Short-Acting B2 Agonists Market 2025, By The Business Research Company

Chronic Cough Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/chronic-cough-global-market-report

Chronic Disease Management Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/chronic-disease-management-global-market-report

Chronic Kidney Disease Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/chronic-kidney-disease-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795